Home - Products - Others - Other Targets - 6,11-Di-O-acetylalbrassitriol

6,11-Di-O-acetylalbrassitriol

CAS No. 110538-20-0

6,11-Di-O-acetylalbrassitriol( —— )

Catalog No. M37758 CAS No. 110538-20-0

6,11-Di-O-acetylalbrassitriol is a metabolite produced by Alternaria brassicae, the black spot pathogen of oilseed rape.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 407 In Stock
5MG 561 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    6,11-Di-O-acetylalbrassitriol
  • Note
    Research use only, not for human use.
  • Brief Description
    6,11-Di-O-acetylalbrassitriol is a metabolite produced by Alternaria brassicae, the black spot pathogen of oilseed rape.
  • Description
    6,11-Di-O-acetylalbrassitriol is a metabolite produced by Alternaria brassicae, the black spot pathogen of oilseed rape.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    110538-20-0
  • Formula Weight
    338.44
  • Molecular Formula
    C19H30O5
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(OCC1(O)C(=CC(OC(=O)C)C2C(C)(C)CCCC21C)C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • alpha-Boswellic acid

    Boswellic acids are a series of pentacyclic triterpene molecules that are produced by plants in the genus Boswellia.

  • SARS-CoV-2 3CLpro-IN...

    SARS-CoV-2 3CLpro-IN-16 is a covalent inhibitor of SARS-CoV-2 3CLpro activity, exerting its effect by forming a covalent bond with Cys145.

  • HA15

    HA15 targets specifically BiP/GRP78/HSPA5. HA15 exhibits anti-cancerous activity on all melanoma cells tested, including cells isolated from patients and cells that developed resistance to BRAF inhibitors.